The Quantellect read.As of Nov 19, 2026, 15 active firms cover Apogee Therapeutics, Inc. Common Stock: 2 rate it Buy or better, 13 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets span $95.00 to $160.00, a moderate spread. The average target of $134.40 is roughly in line with the current $135.07. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-1.37 next quarter toward $-5.20 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS15 active firms
Neutral
Strong Buy00%
Buy213%
Neutral1387%
Sell00%
Strong Sell00%
Based on 15 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$134.40
-0.5% downside
Average target across 13 active firms as of Nov 19, 2026 vs $135.07 current
Highest Target$160.00
Average Target$134.40
Lowest Target$95.00
Detailed analyst forecasts for APGE
Showing 1–15 of 15 named analysts shown · 15 active firms in the rating projection
As of Nov 19, 2026, 2 of 15 active firms rate APGE a Buy (13 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
APGE EPS & revenue forecast
EPS · NEXT QUARTER
$-1.37
Range $-1.40 – $-1.34 · 2 analysts · +33% YoY
Next period, 2 analysts expect Apogee Therapeutics, Inc. Common Stock to earn $-1.37 a share (range $-1.40 – $-1.34), versus $-1.03 a year earlier. Full-year consensus is $-4.86, growing to $-5.20 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $7.1M next year.
Top analysts covering Apogee Therapeutics, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on APGE.
#1
David Nierengarten
Wedbush · Rank #24
Neutral
$135.00-0.1% to target
Overall win rate
48%
+ Follow
#2
SL
Sudan Loganathan
Stephens & Co. · Rank #80
Buy
$95.00-29.7% to target
Overall win rate
47%
+ Follow
#3
Julian Harrison
BTIG · Rank #183
Neutral
No targeton APGE
Overall win rate
41%
+ Follow
#4
EN
Edward Nash
Canaccord Genuity · Rank #270
Neutral
$135.11+0.0% to target
Overall win rate
44%
+ Follow
#5
TA
Tazeen Ahmad
B of A Securities · Rank #411
Buy
$131.00-3.0% to target
Overall win rate
46%
+ Follow
APGE stock forecast FAQ
What is APGE's average 12-month price target?+
The 13 active firms with a live target average $134.40 for Apogee Therapeutics, Inc. Common Stock over the next 12 months, ranging from a $160.00 high to a $95.00 low, as of Nov 19, 2026.
Is APGE stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 15 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 13 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for APGE?+
The Street-high target is $160.00, and the Street-low is $95.00 (Stephens & Co.). The average of all 13 active-firm targets is $134.40.
How many active Wall Street firms cover APGE?+
15 active firms have a recognized rating on Apogee Therapeutics, Inc. Common Stock as of Nov 19, 2026, and 13 active firms carry a live 12-month price target.
Who is the most accurate analyst covering APGE?+
Among analysts who currently cover APGE, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #24). Their current call is Neutral with a $135.00 target.
What is Apogee Therapeutics, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-1.37 per share (range $-1.40 – $-1.34) across 2 analysts. Full-year EPS is projected at $-4.86, rising to $-5.20 the following year.
How much revenue is Apogee Therapeutics, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $7.1M next year.
Have analysts been upgrading or downgrading APGE lately?+
As of Nov 19, 2026, 2 of 15 active firms rate APGE a Buy (13 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their APGE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.